Bio-Gene Technology (ASX:BGT) EV-to-EBIT : -1.54 (As of May. 28, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Bio-Gene Technology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bio-Gene Technology's Enterprise Value is A$4.60 Mil. Bio-Gene Technology's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-2.98 Mil. Therefore, Bio-Gene Technology's EV-to-EBIT for today is -1.54.

The historical rank and industry rank for Bio-Gene Technology's EV-to-EBIT or its related term are showing as below:

ASX:BGT' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.38 Med: -4.57 Max: -0.22
Current: -1.54

During the past 7 years, the highest EV-to-EBIT of Bio-Gene Technology was -0.22. The lowest was -15.38. And the median was -4.57.

ASX:BGT's EV-to-EBIT is ranked worse than
100% of 477 companies
in the Biotechnology industry
Industry Median: 8.27 vs ASX:BGT: -1.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bio-Gene Technology's Enterprise Value for the quarter that ended in Dec. 2024 was A$7.47 Mil. Bio-Gene Technology's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-2.98 Mil. Bio-Gene Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -39.89%.

Bio-Gene Technology EV-to-EBIT Historical Data

The historical data trend for Bio-Gene Technology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Gene Technology EV-to-EBIT Chart

Bio-Gene Technology Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EV-to-EBIT

Get a 7-Day Free Trial

-6.54

-9.00

-4.57

-3.40

-2.47

Bio-Gene Technology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial										-	-3.40	-	-2.47	-

Competitive Comparison of Bio-Gene Technology's EV-to-EBIT

For the Biotechnology subindustry, Bio-Gene Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gene Technology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Bio-Gene Technology EV-to-EBIT Calculation

Bio-Gene Technology's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	4.604	/	-2.981
	=	-1.54

Bio-Gene Technology's current Enterprise Value is A$4.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio-Gene Technology's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-2.98 Mil.

Bio-Gene Technology (ASX:BGT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bio-Gene Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 )	=	EBIT	/	Enterprise Value (Q: Dec. 2024 )
	=	-2.981	/	7.473566
	=	-39.89 %

Bio-Gene Technology's Enterprise Value for the quarter that ended in Dec. 2024 was A$7.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio-Gene Technology's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-2.98 Mil.

Bio-Gene Technology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bio-Gene Technology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Gene Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Gene Technology Ltd (ASX:BGT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000

Website

https://www.bio-gene.com.au

Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance. Its products are Flavocide and Qcide which include a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. The group's product has multiple applications across public health, crop protection, grain storage, and consumer use. It provides new options derived from nature to meet market demand for effective and safe pest management solutions.

Bio-Gene Technology Headlines

From GuruFocus

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

By Business Wire Business Wire • 12-20-2021

BlackRock Floating Rate Income Trust (BGT) Maintains Monthly Dividend Payout

By GuruFocus News • 04-02-2025